On October 9, 2017, California Gov. Jerry Brown signed SB 17, which requires pharmaceutical companies to notify the state and health insurers each time they plan to raise the price of a medication by 16 percent or more over two years. And, interestingly, each pharma company will need to provide justification for the price hike.
“Californians have a right to know why their medical costs are out of control, especially when pharmaceutical profits are soaring,” Brown told NPR. “This measure is a step at bringing transparency, truth, exposure to a very important part of our lives, that is the cost of prescription drugs.”
But there are other health care–related bills that are sitting on Brown’s desk. As reported by The Source on Healthcare Price & Competition—a nonprofit website run by one of HPL’s founders—there are three bills that are still pending in the legislature. These bills include
- granting a state agency the authority to approve all mergers and acquisitions involving a health care plan
- developing a commission to examine health care access and affordability
- preventing hospitals from imposing anti-competitive contract provisions
Read on to learn more about these bills and why they should pass.